BR0012624A - Métodos para a preparação de agentes terapêuticos envolvidos por lipìdeos - Google Patents

Métodos para a preparação de agentes terapêuticos envolvidos por lipìdeos

Info

Publication number
BR0012624A
BR0012624A BR0012624-1A BR0012624A BR0012624A BR 0012624 A BR0012624 A BR 0012624A BR 0012624 A BR0012624 A BR 0012624A BR 0012624 A BR0012624 A BR 0012624A
Authority
BR
Brazil
Prior art keywords
lipid
therapeutic agent
vesicles
preformed
destabilizing
Prior art date
Application number
BR0012624-1A
Other languages
English (en)
Other versions
BR0012624B1 (pt
Inventor
Norbert Maurer
Kim F Wong
Pieter R Cullis
Original Assignee
Inex Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inex Pharmaceuticals Corp filed Critical Inex Pharmaceuticals Corp
Publication of BR0012624A publication Critical patent/BR0012624A/pt
Publication of BR0012624B1 publication Critical patent/BR0012624B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dispersion Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Manufacturing Of Micro-Capsules (AREA)

Abstract

"MéTODOS PARA A PREPARAçãO DE AGENTES TERAPêUTICOS ENVOLVIDOS POR LIPìDEOS". Partículas de um agente terapêutico completamente envolvidas por lipídeos de um agente terapêutico carregado são preparadas através da combinação de uma composição de lipídeos contendo vesículas de lipídeos previamente formadas, um agente terapêutico carregado, e um agente desestabilizante para formar uma mistura de vesículas previamente formadas e agente terapêutico num solvente desestabilizante. O solvente desestabilizante é eficaz para desestabilizar a membrana das vesículas de lipídeos previamente formadas sem romper as vesículas. A mistura resultante é incubada por um período de tempo suficiente para permitir o encapsulamento do agente terapêutico dentro das vesículas de lipídeos previamente formadas. O agente desestabilizante é então removido para produzir partículas de um agente terapêutico completamente envolvidas por lipídeos. As vesículas de lipídeos previamente formadas compreendem um lipídeo carregado que apresenta uma carga que é oposta à carga do agente terapêutico carregado e um lipídeo modificado apresentando uma componente de barreira esteárica para o controle da agregação. O lipídeo modificado está presente dentro das vesículas previamente formadas numa quantidade eficaz para retardar, porém não impedir, a agregação das vesículas previamente formadas. Numa incorporação preferencial da presente invenção, eficaz no sentido de proporcionar uma formação de partículas de lipídeos eficiente em larga escala (por exemplo 20-200 litros), uma solução de agente terapêutico compreendendo ácidos nucleicos (por exemplo oligodeoxinucleotídeos antisense) é combinada com vesículas de lipídeos previamente formadas numa solução 25-40 % de etanol aquoso. A incubação desta mistura por um período de cerca de 1 hora é suficiente para resultar na produção espontânea de partículas de agente terapêutico completamente encapsuladas.
BRPI0012624-1A 1999-07-15 2000-07-14 métodos para a preparação de agentes terapêuticos envolvidos por lipìdeos. BR0012624B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14397899P 1999-07-15 1999-07-15
US60/143,978 1999-07-15
PCT/CA2000/000843 WO2001005374A1 (en) 1999-07-15 2000-07-14 Methods for preparation of lipid-encapsulated therapeutic agents

Publications (2)

Publication Number Publication Date
BR0012624A true BR0012624A (pt) 2002-04-02
BR0012624B1 BR0012624B1 (pt) 2011-08-09

Family

ID=22506531

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0012624-1A BR0012624B1 (pt) 1999-07-15 2000-07-14 métodos para a preparação de agentes terapêuticos envolvidos por lipìdeos.

Country Status (11)

Country Link
EP (2) EP1196145A1 (pt)
JP (3) JP2003504390A (pt)
CN (1) CN1228041C (pt)
AT (1) ATE286719T1 (pt)
AU (2) AU771706B2 (pt)
BR (1) BR0012624B1 (pt)
CA (2) CA2378438C (pt)
DE (1) DE60017406T2 (pt)
ES (1) ES2235916T3 (pt)
IL (2) IL147089A0 (pt)
WO (2) WO2001005373A1 (pt)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020119188A1 (en) * 2000-02-08 2002-08-29 Susan Niemiec Method of manufacturing liposomes
US7189705B2 (en) 2000-04-20 2007-03-13 The University Of British Columbia Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers
AU5454801A (en) * 2000-04-20 2001-11-07 Univ British Columbia Methods of enhancing splp-mediated transfection using endosomal membrane destabilizers
JP2005530704A (ja) * 2002-03-05 2005-10-13 トランセイブ， インク． 細胞内感染を予防及び治療するための吸入システム
WO2003097805A2 (en) 2002-05-15 2003-11-27 California Pacific Medical Center Delivery of nucleic acid-like compounds
EP1530465B2 (en) 2002-06-26 2015-12-16 MediGene AG Method of producing a cationic liposomal preparation comprising a lipophilic compound
EP1519714B1 (en) 2002-06-28 2010-10-20 Protiva Biotherapeutics Inc. Method and apparatus for producing liposomes
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
CA2532228C (en) * 2003-07-16 2017-02-14 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
WO2006069782A2 (en) 2004-12-27 2006-07-06 Silence Therapeutics Ag. Lipid complexes coated with peg and their use
MXPA06012722A (es) 2004-05-05 2007-02-14 Atugen Ag Lipidos, complejos de lipido y su uso.
JP4764426B2 (ja) * 2004-06-07 2011-09-07 プロチバ バイオセラピューティクス インコーポレイティッド カチオン性脂質および使用方法
CA2569664C (en) 2004-06-07 2013-07-16 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
EP1773857A4 (en) 2004-07-02 2009-05-13 Protiva Biotherapeutics Inc THE IMMUNE SYSTEM STIMULATING SIRNA MOLECULES AND APPLICATIONS THEREOF
CN101267805A (zh) 2005-07-27 2008-09-17 普洛体维生物治疗公司 制造脂质体的系统和方法
CN101346393B (zh) 2005-11-02 2015-07-22 普洛体维生物治疗公司 修饰的siRNA分子及其应用
EP3067047B1 (en) 2005-12-08 2022-04-20 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections
EP2004141A2 (en) * 2006-03-17 2008-12-24 Novosom AG An efficient method for loading amphoteric liposomes with nucleic acid active substances
EP2012750B1 (en) * 2006-04-06 2018-02-21 Insmed Incorporated Methods for coacervation induced liposomal encapsulation and formulations thereof
KR101670085B1 (ko) 2006-07-21 2016-10-28 사일런스 테라퓨틱스 게엠베하 단백질 키나아제 3의 발현을 억제하기 위한 수단
WO2008137717A1 (en) 2007-05-04 2008-11-13 Transave, Inc. Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods and uses thereof
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
WO2009038540A1 (en) * 2007-09-17 2009-03-26 Microspace Rapid Pte Ltd System and method for providing control of a vehicle
CA2721333C (en) 2008-04-15 2020-12-01 Protiva Biotherapeutics, Inc. Novel lipid formulations for nucleic acid delivery
CA2740000C (en) 2008-10-09 2017-12-12 Tekmira Pharmaceuticals Corporation Improved amino lipids and methods for the delivery of nucleic acids
JP2012505913A (ja) 2008-10-16 2012-03-08 マリーナ バイオテック，インコーポレイテッド 遺伝子発現を抑制する治療におけるリポソームによる効率的な送達のプロセスおよび組成物
CN111808084A (zh) 2008-11-10 2020-10-23 阿布特斯生物制药公司 用于递送治疗剂的新型脂质和组合物
EA020604B1 (ru) * 2008-12-17 2014-12-30 Онкотиреон, Инк. Композиция, содержащая липосомы малого размера, и способ ее получения
WO2011000107A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Novel lipid formulations for delivery of therapeutic agents to solid tumors
EP2449106B1 (en) 2009-07-01 2015-04-08 Protiva Biotherapeutics Inc. Compositions and methods for silencing apolipoprotein b
US9018187B2 (en) 2009-07-01 2015-04-28 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
JP5854559B2 (ja) 2009-07-06 2016-02-09 ヴァリエーション バイオテクノロジーズ インコーポレイテッド 小胞を調製する方法及びこれから製造される製剤
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
WO2011056682A1 (en) 2009-10-27 2011-05-12 The University Of British Columbia Reverse head group lipids, lipid particle compositions comprising reverse headgroup lipids, and methods for the delivery of nucleic acids
WO2011120023A1 (en) 2010-03-26 2011-09-29 Marina Biotech, Inc. Nucleic acid compounds for inhibiting survivin gene expression uses thereof
US20130037977A1 (en) 2010-04-08 2013-02-14 Paul A. Burke Preparation of Lipid Nanoparticles
WO2011133584A2 (en) 2010-04-19 2011-10-27 Marina Biotech, Inc. Nucleic acid compounds for inhibiting hras gene expression and uses thereof
WO2011139843A2 (en) 2010-04-28 2011-11-10 Marina Biotech, Inc. Multi-sirna compositions for reducing gene expression
US9006417B2 (en) 2010-06-30 2015-04-14 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
WO2012006367A2 (en) 2010-07-06 2012-01-12 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
US10736844B2 (en) * 2011-01-13 2020-08-11 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
EP3485875A1 (en) * 2011-11-04 2019-05-22 Nitto Denko Corporation Single use system for sterelily producing lipid-nucleic acid particles
US9579338B2 (en) * 2011-11-04 2017-02-28 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
AU2013208693B2 (en) 2012-01-12 2017-12-07 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
EP2806894A4 (en) 2012-01-27 2015-11-04 Variation Biotechnologies Inc METHODS AND COMPOSITIONS FOR THERAPEUTIC AGENTS
PL2852391T3 (pl) 2012-05-21 2022-04-11 Insmed Incorporated Układy do leczenia infekcji płuc
US10124066B2 (en) 2012-11-29 2018-11-13 Insmed Incorporated Stabilized vancomycin formulations
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
EP2968141B1 (en) * 2013-03-14 2016-10-05 Biorest Ltd. Liposome formulation and manufacture
US9693958B2 (en) 2013-03-15 2017-07-04 Cureport, Inc. Methods and devices for preparation of lipid nanoparticles
US10542918B2 (en) 2013-10-23 2020-01-28 Verily Life Sciences Llc Modulation of a response signal to distinguish between analyte and background signals
US9636034B2 (en) 2013-10-23 2017-05-02 Verily Life Sciences Llc Non-invasive analyte detection system with modulation source
LT3466432T (lt) 2014-05-15 2020-12-28 Insmed Incorporated Būdai, skirti plaučių netuberkuliozinėms mikobakterinėms infekcijoms gydyti
BR112016030852A2 (pt) * 2014-07-02 2018-01-16 Shire Human Genetic Therapies encapsulação de rna mensageiro
US9861710B1 (en) 2015-01-16 2018-01-09 Verily Life Sciences Llc Composite particles, methods, and in vivo diagnostic system
US12491261B2 (en) 2016-10-26 2025-12-09 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
AU2017357758B2 (en) * 2016-11-10 2023-11-16 Translate Bio, Inc. Improved process of preparing mRNA-loaded lipid nanoparticles
MA49421A (fr) 2017-06-15 2020-04-22 Modernatx Inc Formulations d'arn
EP3675817A1 (en) 2017-08-31 2020-07-08 Modernatx, Inc. Methods of making lipid nanoparticles
RS67724B1 (sr) * 2017-10-20 2026-03-31 BioNTech SE Priprema i skladištenje lipozomskih rnk formulacija koje su pogodne za terapiju
EP3773505B1 (en) 2018-03-30 2026-04-29 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
JP7449275B2 (ja) 2018-05-02 2024-03-13 インスメッド インコーポレイテッド リポソーム薬物製剤の製造方法
KR20210091120A (ko) 2018-08-29 2021-07-21 트랜슬레이트 바이오 인코포레이티드 Mrna-로딩된 지질 나노입자를 제조하는 개선된 공정
EP3620519A1 (en) * 2018-09-04 2020-03-11 F. Hoffmann-La Roche AG Use of isolated milk extracellular vesicles for delivering oligonucleotides orally
WO2020061457A1 (en) 2018-09-20 2020-03-26 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
RU2697390C1 (ru) * 2019-03-15 2019-08-14 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кемеровский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ синтеза липосомальной формы тироксина
SG11202110036RA (en) 2019-03-19 2021-10-28 Arcturus Therapeutics Inc Method of making lipid-encapsulated rna nanoparticles
EP3711749A1 (en) 2019-03-19 2020-09-23 Polymun Scientific Immunbiologische Forschung GmbH Method of making lipid nanoparticles
CN118203546A (zh) 2019-05-07 2024-06-18 米尼翁大学 生产脂质体的方法
CN115427021A (zh) 2020-02-25 2022-12-02 翻译生物公司 制备负载mrna的脂质纳米颗粒的改进方法
ES3054438T3 (en) 2020-07-16 2026-02-03 Acuitas Therapeutics Inc Cationic lipids for use in lipid nanoparticles
IL301253A (en) 2020-09-13 2023-05-01 Arcturus Therapeutics Inc As a mass of large RNA lipid nanoparticles
WO2022115645A1 (en) 2020-11-25 2022-06-02 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids, and related methods of use
EP4059491A1 (de) 2021-03-17 2022-09-21 Evonik Operations GmbH Vorrichtung und verfahren zur herstellung von nanocarriern und/oder nanoformulierungen
CA3242402A1 (en) 2021-12-16 2023-06-22 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
CA3256897A1 (en) 2022-05-25 2023-11-30 Akagera Medicines, Inc. Lipid nanoparticles for the administration of nucleic acids and their methods of use
EP4584011A1 (en) 2022-09-08 2025-07-16 Evonik Operations GmbH Improved nanocarrier manufacturing
EP4669453A1 (en) 2023-02-23 2025-12-31 Evonik Operations GmbH EASY-TO-HANDLE LIPOSOME EXTRUDER
CN120769775A (zh) 2023-02-23 2025-10-10 赢创运营有限公司 小型脂质体挤出器
WO2025219199A1 (en) 2024-04-19 2025-10-23 Evonik Operations Gmbh Process for producing nanocarriers and/or nanoformulations

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4752425A (en) * 1986-09-18 1988-06-21 Liposome Technology, Inc. High-encapsulation liposome processing method
US4895452A (en) * 1988-03-03 1990-01-23 Micro-Pak, Inc. Method and apparatus for producing lipid vesicles
JPH0665382B2 (ja) * 1991-03-20 1994-08-24 雪印乳業株式会社 リポソーム調製装置とその装置を使用するリポソーム調製方法
US5776486A (en) * 1993-05-28 1998-07-07 Aphios Corporation Methods and apparatus for making liposomes containing hydrophobic drugs
CA2163860A1 (en) * 1993-06-30 1995-01-12 Chung C. Hsu Method for preparing liposomes
EP1179340A3 (en) * 1994-09-30 2003-05-07 INEX Pharmaceutical Corp. Compositions for the introduction of polyanionic materials into cells
AU733310C (en) * 1997-05-14 2001-11-29 University Of British Columbia, The High efficiency encapsulation of charged therapeutic agents in lipid vesicles
CA2309727C (en) * 1997-10-10 2012-12-04 Inex Pharmaceuticals Corporation Methods for encapsulating nucleic acids in lipid bilayers
AU752802C (en) * 1997-11-14 2006-04-13 Pacira Pharmaceuticals, Inc. Production of multivesicular liposomes
WO2000029103A1 (en) * 1998-11-13 2000-05-25 Optime Therapeutics, Inc. Method and apparatus for liposome production

Also Published As

Publication number Publication date
BR0012624B1 (pt) 2011-08-09
JP2011225618A (ja) 2011-11-10
DE60017406T2 (de) 2005-09-29
AU6256100A (en) 2001-02-05
CN1361681A (zh) 2002-07-31
JP5388395B2 (ja) 2014-01-15
WO2001005373A1 (en) 2001-01-25
DE60017406D1 (de) 2005-02-17
WO2001005373A9 (en) 2002-08-29
ATE286719T1 (de) 2005-01-15
AU771706B2 (en) 2004-04-01
ES2235916T3 (es) 2005-07-16
IL147089A (en) 2006-08-20
JP2003504391A (ja) 2003-02-04
CA2378438C (en) 2010-05-04
JP2003504390A (ja) 2003-02-04
AU769357B2 (en) 2004-01-22
WO2001005374A1 (en) 2001-01-25
CA2378438A1 (en) 2001-01-25
EP1194122B1 (en) 2005-01-12
IL147089A0 (en) 2002-08-14
EP1196145A1 (en) 2002-04-17
CA2378430A1 (en) 2001-01-25
AU6256200A (en) 2001-02-05
CN1228041C (zh) 2005-11-23
EP1194122A1 (en) 2002-04-10

Similar Documents

Publication Publication Date Title
BR0012624A (pt) Métodos para a preparação de agentes terapêuticos envolvidos por lipìdeos
ATE324907T1 (de) Verbindung und arzneizusammensetzung zur verabreichung von wirkstoffen
AU7315301A (en) Compounds and compositions for delivering active agents
MXPA01008611A (es) Compuestos y composiciones para suministrar agentes activos.
IL140930A0 (en) Compounds and compositions for delivering active agents
NO20005431D0 (no) Gelérbare farmasøytiske preparater
ATE191452T1 (de) Dichtgepackte polykationische ammonium, sulfonium und phosphonium lipide
AU4711296A (en) Method for loading lipid vesicles
GR3003046T3 (en) Liposome composition
IL195055A (en) Carboxylic acid components and compounds for transporting active carriers
GR3036792T3 (en) New bi- and tricyclic aminoalcohol esters, their preparation and their use in medicaments.
AP9801169A0 (en) N-hydroxy-B-sulfonyl propionamide derivatives.
BR9510168A (pt) Composto poliaminoácido composição forma unitária de dosagem e método par epreparar uma composição
CA2360220A1 (en) Oxadiazole compounds and compositions for delivering active agents
WO2003028758A1 (en) Novel method of inducing antigen-specific t cells
BR0015256A (pt) Composições farmacêuticas contendo uma droga de antibiótico de fluoroquinolona e uma goma de xantano
HRP20050546B1 (hr) Priprava sterilnih vodenih suspenzija koja obuhvaä†a usitnjene kristaliniäśne sastojke za inhalaciju
WO2002015959A3 (en) Compounds and compositions for delivering active agents
IT1263840B (it) Formulazioni orali di ubidecarenone in forma di capsule
UA66812C2 (uk) Препаративна форма лікарського засобу із регульованим вивільненням активної речовини
ES2134237T3 (es) Composiciones farmaceuticas que contienen acido ursodesoxicolico.
GEP19991872B (en) Novel Taxoids, Preparations Thereof, and Pharmaceutical Compositions Containing Same
AU1712700A (en) Restoration of platelet aggregation by antibody administration after gpiib/iiia antagonist treatment
ATE267585T1 (de) Micronisierte pharmazeutische zusammensetzungen
BR9807694A (pt) de um princìpio ativo

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: THE UNIVERSITY OF BRITISH COLUMBIA (CA)

Free format text: TRANSFERIDO DE: INEX PHARMACEUTICALS CORP.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]

Free format text: DE ACORDO COM ART. 34 " II " DA LPI ( LEI 9279, DE 14/05/96 ) , O EXAME FICA SUSPENSO PARA QUE O REQUERENTE APRESENTE DOCUMENTOS NECESSARIOS A REGULARIZACAO DO PROCESSO E EXAME DO PEDIDO.

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/08/2011, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 13A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2259 DE 22-04-2014 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.